Gain Therapeutics
Develops allosteric medicines and rexaceract for Parkinson’s disease.
$1.77
After-hours close0.00 (0.00%)
At close$1.77(−4.32%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 19.21%Insiders —
Shares outstanding 42.65M · Float 41.65M · 97.6% free float
Insiders — no current Form 4 position.
Institutions13F, as of Mar 31, 2026
46 holders · 8.19M shares · 9 new positions · 19 increased · 10 reduced · 16 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Marshall Wace, LLP | 1.77M | 4.15% | +107.5K | May 15, 2026 |
| Potomac Capital Management, Inc. | 1.01M | 2.36% | −1.4K | May 14, 2026 |
| Jones Financial Companies LLLP | 631.6K | 1.48% | −70.6K | May 15, 2026 |
| Cambridge Investment Research Advisors, Inc. | 568.6K | 1.33% | 0 | Apr 30, 2026 |
| Dme Capital Management, LP | 566.1K | 1.33% | 0 | May 15, 2026 |
| Geode Capital Management, LLC | 447.3K | 1.05% | +49.4K | May 15, 2026 |
| Susquehanna International Group, LLP | 431.3K | 1.01% | −253.1K | May 15, 2026 |
| Vanguard Capital Management LLC | 399.9K | 0.94% | +399.9Knew | May 15, 2026 |
Beneficial owners13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
InsidersForm 4
No current Form 4 position on record.
6 people have not refiled in the last 18 months (396.2K shares), so they are not in the figure above
Latest trades
No open-market trades in the last 12 months.
CongressHouse and Senate disclosures
Not reported.